Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: A long-term follow-up study

Endocrine Journal

Volumn 60, Issue 6, 2013, Pages 715-724

  Fukui, Tomoyasu ^a   Oono, Kayoko ^a   Hara, Noriko ^a   Yamamoto, Takeshi ^a   Nagashima, Masaharu ^a   Naito, Hirokuni ^b   Hirano, Tsutomu ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Naito Hospital   (Japan)

Author keywords

cell function; Glucagon test; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; JAPANESE; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC TECHNIQUES, ENDOCRINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLUCAGON; HUMANS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME; UP-REGULATION;

EID: 84879682247     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ12-0357     Document Type: Article

References (30)

1. Defronzo RA (2009) Banting Lecture. From the tri-umvirate of the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
2. U.K. Prospective Diabetes Study Group (1995) U.K. prospective diabetes study 16. Overview of 6 years' ther-apy of type 2 diabetes: a progressive disease. Diabetes 44: 1249-1258.
3. Meier JJ, Menge BA, Breuer TG, Müller CA, Tannapfel A, et al. (2009) Functional assessment of pancreatic beta-cell area in humans. Diabetes 58:1595-1603.
4. Stiller CR, Dupré J, Gent M, Jenner MR, Keown PA, et al. (1984) Effects of cyclosporine immunosuppressionin insulin-dependent diabetes mellitus of recent onset. Science 223: 1362-1367.
5. Gjessing HJ, Matzen LE, Faber OK, Frøland A (1989) Fasting plasma Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes. Diabetologia 32: 305-311.
6. Gjessing HJ, Reinhold B, Pedersen O (1992) The effect of chronic hyperglycaemia on the islet B-cell respon-siveness in newly diagnosed type 2 diabetes. Diabet Med 9:601-604.
7. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppälä P (1986) Plasma and urinary C-peptide in the classifica-tion of adult diabetics. Scand J Clin Lab Invest 46:655-663.
8. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, et al. (1981) Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treat-ment in diabetes mellitus. Acta Med Scand 210: 153-156.
9. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34: 222-234.
10. Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, et al. (2008) Analysis of factors influencing pancreatic beta-cell function in Japanese patients with type 2 diabetes: association with body mass index and duration of diabetic exposure. Diabetes Res Clin Pract 82: 353-358.
11. Yamada Y, Fukuda K, Fujimoto S, Hosokawa M, Tsukiyama K, et al. (2006) SUIT, secretory units of islets in transplantation: An index for therapeutic manage-ment of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 74: 222-226.
12. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 1: 212-228.
13. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
14. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, et al. (2002) Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 45: 85-96.
15. Pratley RE, Weyer C (2001) The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. Diabetologia 44: 929-945.
16. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE (1978) Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes 27:715-725.
17. Scheen AJ, Castillo MJ, Lefèbvre PJ (1996) Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodolog-ical aspects and clinical applications. Diabetes Metab 22: 397-406.
18. Donath MY, Halban PA (2004) Decreased beta-cell mass in diabetes: significance, mechanisms and thera-peutic implications. Diabetologia 47: 581-589.
19. Prentki M, Nolan CJ (2006) Islet beta cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812.
20. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, et al. (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90: 501-506.
21. Leahy JL, Cooper HE, Deal DA, Weir GC (1986) Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in nor-mal rats using chronic in vivo glucose infusions. J Clin Invest 77: 908-915.
22. Unger RH, Grundy S (1985) Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28: 119-121.
23. Eizirik DL, Korbutt GS, Hellerström C (1992) Prolonged exposure of human pancreatic islets to high glucose concentrations in vitro impairs the beta-cell function. J Clin Invest 90: 1263-1268.
24. Marshak S, Leibowitz G, Bertuzzi F, Socci C, Kaiser N, et al. (1999) Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. Diabetes 48: 1230-1236.
25. Harrower AD (1994) Comparison of efficacy, second-ary failure rate, and complications of sulfonylureas. J Diabetes Complications 8: 201-203.
26. Stenman S, Melander A, Groop PH, Groop LC (1993) What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 118: 169-172.
27. Rustenbeck I (2002) Desensitization of insulin secre-tion.Biochem Pharmacol 63: 1921-1935.
28. Yki-Jarvinen H (1992) Glucose toxicity. Endocr Rev 13: 415-431.
29. Noh YH, Lee WJ, Kim KA, Lim I, Lee JH, et al. (2010) Insulin requirement profiles of patients with type 2 dia-betes after achieving stabilized glycemic control with short-term continuous subcutaneous insulin infusion. Diabetes Technol Ther 12: 271-281.
30. Chen A, Huang Z, Wan X, Deng W, Wu J, et al. (2012) Attitudes toward diabetes affect maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insu-lin infusion treatment. Diabetes Care 35: 474-481.